Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences (NYSE:RCUS) has announced new employment inducement grants for its recently appointed Chief Medical Officer, Dr. Richard Markus, and two new employees. Dr. Markus received an option to purchase 305,328 shares of common stock at $12.45 per share and restricted stock units for 75,193 shares. Additionally, two new employees were granted options to purchase 9,150 shares at $12.45 per share and restricted stock units for 4,600 shares. These equity awards were granted under the Company's 2020 Inducement Plan, approved under NYSE Listed Company Manual Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS) ha annunciato nuove concessioni di assunzione per il suo recentemente nominato Chief Medical Officer, Dr. Richard Markus, e due nuovi dipendenti. Il Dr. Markus ha ricevuto un'opzione per acquistare 305.328 azioni di azioni ordinarie a $12,45 per azione e unità di azioni vincolate per 75.193 azioni. Inoltre, due nuovi dipendenti hanno ricevuto opzioni per acquistare 9.150 azioni a $12,45 per azione e unità di azioni vincolate per 4.600 azioni. Questi premi azionari sono stati concessi ai sensi del Piano di Induzione 2020 dell'azienda, approvato secondo l'eccezione di induzione della Regola 303A.08 del Manuale delle Aziende quotate della NYSE.
Arcus Biosciences (NYSE:RCUS) ha anunciado nuevas concesiones de contratación para su recientemente nombrado Director Médico, Dr. Richard Markus, y dos nuevos empleados. El Dr. Markus recibió una opción para comprar 305,328 acciones de acciones comunes a $12.45 por acción y unidades de acciones restringidas para 75,193 acciones. Además, se otorgaron opciones a dos nuevos empleados para comprar 9,150 acciones a $12.45 por acción y unidades de acciones restringidas para 4,600 acciones. Estas concesiones de acciones se otorgaron bajo el Plan de Inducción 2020 de la empresa, aprobado según la excepción de inducción de la Regla 303A.08 del Manual de Empresas Cotizadas de la NYSE.
Arcus Biosciences (NYSE:RCUS)는 최근 임명된 최고 의료 책임자인 Richard Markus 박사 및 두 명의 신입 직원에게 새로운 고용 유인 보상을 발표했습니다. Markus 박사는 305,328 주식을 주당 $12.45에 매수할 수 있는 옵션과 75,193 주식의 제한된 주식 단위를 받았습니다. 또한, 새로운 두 명의 직원은 9,150 주식을 주당 $12.45에 매수할 수 있는 옵션과 4,600 주식의 제한된 주식 단위를 부여받았습니다. 이러한 주식 보상은 NYSE 상장 기업 매뉴얼 규칙 303A.08의 유인 예외에 따라 승인된 회사의 2020 유인 계획에 따라 부여되었습니다.
Arcus Biosciences (NYSE:RCUS) a annoncé de nouvelles incitations à l'emploi pour son nouveau Chief Medical Officer, Dr. Richard Markus, et deux nouveaux employés. Le Dr. Markus a reçu une option pour acheter 305,328 actions d'actions ordinaires à 12,45 $ par action et des unités d'actions restreintes pour 75,193 actions. De plus, deux nouveaux employés ont reçu des options d'achat de 9,150 actions à 12,45 $ par action et des unités d'actions restreintes pour 4,600 actions. Ces attributions d'actions ont été accordées dans le cadre du Plan d'incitation 2020 de l'entreprise, approuvé en vertu de l'exception d'incitation de la règle 303A.08 du Manuel des entreprises cotées à la NYSE.
Arcus Biosciences (NYSE:RCUS) hat neue Beschäftigungsanreize für seinen neu ernannten Chief Medical Officer, Dr. Richard Markus, und zwei neue Mitarbeiter angekündigt. Dr. Markus erhielt eine Option zum Kauf von 305.328 Aktien zum Preis von $12,45 pro Aktie sowie eingeschränkte Aktieneinheiten für 75.193 Aktien. Darüber hinaus erhielten zwei neue Mitarbeiter Optionen zum Kauf von 9.150 Aktien zum Preis von $12,45 pro Aktie und eingeschränkte Aktieneinheiten für 4.600 Aktien. Diese Eigenkapitalzuwendungen wurden im Rahmen des Unternehmensplans für Anreize von 2020 gewährt, der gemäß der Anreizausnahme der Regel 303A.08 des Handbuchs für an der NYSE gelistete Unternehmen genehmigt wurde.
- Successful recruitment of new Chief Medical Officer indicates strategic executive team expansion
- Structured equity compensation plan demonstrates ability to attract key talent
- Potential dilution of existing shareholders from new equity grants
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, A2a/A2b receptors, CD39 and AXL. For more information about Arcus Biosciences’s clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211993303/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Maryam Bassiri
AD, Corporate Communications
(510) 406-8520
mbassiri@arcusbio.com
Source: Arcus Biosciences
FAQ
What equity compensation did RCUS grant to its new Chief Medical Officer?
How many shares were granted to new employees in RCUS's February 2025 inducement grants?
What was the exercise price for RCUS's February 2025 stock options grants?
Under which plan were RCUS's February 2025 equity awards granted?
